Abstract
This analysis by Marketdata examines a controversial $4 billion healthcare
service sector - infertility services. This loosely regulated “baby
business” has come under the spotlight lately, as the Nadya Suleman
(OctoMom) case brought up issues of unethical practices by some fertility
doctors practicing “assisted reproductive technology” (ART) and
implanting multiple embryos.
ART now produces more than 50,000 babies per year in the U.S. via 142,000 IVF
procedures (nearly tripled since 1999), and demand is growing from the ranks
of 7+ million infertile women, many of which delayed childbearing due to
careers. There are 483 U.S. fertility clinics, 100+ sperm banks, an unknown
number of egg donors, and 1,700 reproductive endocrinologists competing for
the business, which is lucrative. In addition, the global market for
fertility drugs tops $1 billion. Only one corporate “chain”,
IntegraMed, exists, as most programs are run by small MD practices or are part
of a hospital or University.
This unique new study by Marketdata examines the nature/evolution of the
business, national receipts/growth from 1988 to 2013 forecast, extensive
infertile customer demographics, key industry trends, industry regulation,
pricing, industry consolidation, insurance coverage, ethical issues and calls
for reform, effects of the recession, and more. The study presents the
findings of Marketdata' s mail/phone survey of fertility clinic managers, with
average costs and number of specific diagnostic procedures. Contains results
of the latest (2006 & 2007) CDC ART surveys, with IVF success rates, plus a
name/address directory of 400+ fertility clinics, as well as European ART
cycles survey data. Examines the sperm banks, egg donors, and fertility drugs
markets, and surrogacy programs.
This study is believed to be one of the few in-depth publicly available
business analyses that exists of this market. It' s All here in one place.
| 
View Cart
